secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0001641172-25-006043
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra enters up to $20M equity line with Alumni Capital for clinical pipeline funding
--------------------------------------------------------------------------------

- Purchase Agreement with Alumni Capital LP for up to $20M of common stock and warrants over 20 months.
- Azitra controls timing/amount of sales; purchase price at 90% of lowest VWAP during pricing period.
- Each purchase includes warrants for 10% of shares at 130% of purchase price, exercisable for 5 years subject to shareholder approval.
- Company must register resale of shares within 60 days; issuance exempt under Section 4(a)(2).
- Proceeds to advance pipeline for Netherton Syndrome and EGFRi-associated rash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000164117225006043/0001641172-25-006043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000164117225006043/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-006043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer